新冠肺炎專區
新冠病毒疫苗介紹
新冠病毒疫苗介紹

輝瑞/BioNTech mRNA 疫苗的保護力

(出現症狀且實驗室證實的新冠病毒感染)

  • 43,548受試者≥16歲1:1隨機分派接受疫苗或安慰 劑
  • Efficacy in prevention of symptomatic Covid19 illness
  • Per-protocol 95.0% (95% CI, 90.0% - 97.9%)
  • Intention-to-treat 94.8% (95% CI, 89.8% - 97.6%) 
  • 打完第一劑 52.0%
  • 打完第一劑未打第二劑 52.4%
  • 打完第二劑的7天之內 90.5%
  • 打完第二劑的7天之後 94.8% New Engl J Med 383, 2603–2615 (2020)

莫德那(Moderna) mRNA 疫苗保護力

(出現症狀且實驗室證實的新冠病毒感染)

• 30,420受試者≥18歲1:1隨機分派接受疫苗或安慰劑

• Efficacy in prevention of symptomatic Covid19 illness

• All patients 94.1% (95% CI, 89.3% - 96.9%)

• ≥18 to < 65 yr 95.6% (95% CI, 90.6% - 97.9%)

• ≥ 65 yr 86.4% (95% CI, 61.4% - 95.2%)

• 打完第一劑後14天內 54.4% • 打完第一劑14天至打第二劑前 94.3%

• 打完第二劑的14天之內 100.0%

• 打完第二劑的14天之後 94.1% New Engl J Med 384, 403–416 (2020)

 

AZ腺病毒載體疫苗的保護力

(出現症狀且實驗室證實的新冠病毒感染)

• 11,636受試者≥18歲1:1隨機分派接受試驗或對照疫苗

• Efficacy in prevention of symptomatic Covid-19 illness

• All recipients 70.4% (95% CI, 54.8% - 80.6%)

• LD/SD recipients (≤55yr) 90.0% (95% CI, 67.4% - 90.0%)

• SD/SD recipients 62.1% (95% CI, 41.0% - 75.7%)

• 18-55 yr-o, >8wks interval

• LD/SD recipients 90.0% (95% CI, 67.3% - 97.0%)

• SD/SD recipients 65.6% (95% CI, 24.5% - 84.4%)

• All SD/SD • <6 wks interval 53.4% (95% CI, -2.5%–78.8%)

• ≥6 wks interval 65.4% (95% CI, 4.1% - 79.6%) Lancet 397, 99–111 (2021)